依达拉奉不良反应的文献分析  

Document analysis of adverse reactions of edaravone

作　　者：王淑洁[1] 张建华[1] 李俊英[1] 王秀云[1] 陈锋[1] 陆红柳[2] 

机构地区：[1]首都医科大学宣武医院药剂科,北京100053 [2]北京垂杨柳医院药剂科,北京100053

出　　处：《实用药物与临床》2009年第6期446-447,共2页Practical Pharmacy and Clinical Remedies

摘　　要：目的了解依达拉奉的安全性,为临床更安全有效地使用该药提供有价值的信息。方法通过《中国期刊网全文数据库》(CHKD),检索2007-2008年发表的有关依达拉奉的临床研究文献。筛选用药中进行不良反应监测的文献,进行汇总分析。结果共获得符合条件的病例报道77篇,涉及病例3096例。发生ADR的病例185例次,占全部病例的5.96%。依达拉奉的ADR以转氨酶升高以及皮肤损害、肾功能损害发生率较高,分别为42.70%、19.46%和12.43%。结论依达拉奉主要的不良反应是转氨酶升高、皮疹和肾功能损害,临床安全性较好。Objective To analyze the safety of edaravone,provide valuable information for safe and effective use of edaravone in clinic.Methods The clinical research articles about edaravone were searched by China Academic Journals Full-text Database （CHKD） from 2007 to 2008.The articles were screened that include monitoring the adverse drug reactions （ADR） of edaravone.Results 77 articles that involved in 3 096 cases were gained.185 cases （5.96%） appeared ADR.185 cases occurred ADR of edaravone that contained elevation of aminotransferase,skin rash and renal function lesion （42.70%,19.46% and 12.43%）.Conclusion The elevation of aminotransferase,skin rash and renal function lesion are the mostly common ADR of edaravone.Edaravone is comparatively safe in clinical use.

关 键 词：依达拉奉 药品不良反应 

分 类 号：R971[医药卫生—药品]